|
|
Time |
Source |
|
Announcement
|
|
| 15 Mar 2021 |
10:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
New Zolgensma data demonstrate age-appropriate development when used early, real-world benefit in older children and durability 5+ years post-treatment |
| 09 Mar 2021 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis provides update on Phase III study evaluating canakinumab (ACZ885) as second or third-line treatment in combination with chemotherapy in non-small cell lung cancer |
| 05 Mar 2021 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces change to the Executive Committee |
| 02 Mar 2021 |
2:26 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis shareholders approve all resolutions proposed by the Board of Directors at the Annual General Meeting |
| 17 Feb 2021 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis and the Bill & Melinda Gates Foundation collaborate to discover and develop an accessible in vivo gene therapy for sickle cell disease |
| 16 Feb 2021 |
6:22 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Entresto® granted expanded indication in chronic heart failure by FDA |
| 11 Feb 2021 |
12:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Sandoz announces agreement to acquire GSK’s cephalosporin antibiotics business, reinforcing its leading global position in antibiotics |
| 26 Jan 2021 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis delivered sales growth and margin expansion. Continued to progress its next wave of medicines in 2020. |
| 11 Jan 2021 |
9:30 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis expands Oncology pipeline with in-licensing of tislelizumab from BeiGene |
| 18 Dec 2020 |
9:50 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis receives complete response letter from U.S. FDA for inclisiran |
| 16 Dec 2020 |
12:17 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces positive FDA Advisory Committee recommendation for use of Entresto® to treat patients with HFpEF |
| 14 Dec 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis provides update on RUXCOVID study of ruxolitinib for hospitalized patients with COVID-19 |
| 09 Dec 2020 |
2:45 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Kisqali® data demonstrate superior benefit across main intrinsic subtypes in metastatic breast cancer |
| |
2:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Kisqali® demonstrates nearly five years median overall survival in metastatic breast cancer |
| 08 Dec 2020 |
3:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis investigational STAMP inhibitor asciminib (ABL001) shows superior MMR rate to Bosulif®* in chronic myeloid leukemia trial |
| 05 Dec 2020 |
3:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis analyses confirm benefit of Kymriah® with clinically meaningful rates of complete response seen in patients with certain advanced lymphomas |
| 04 Dec 2020 |
5:30 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces first data from REACH3 trial showing Jakavi® (ruxolitinib) significantly improved outcomes in patients with steroid-resistant/dependent chronic GvHD |
| 24 Nov 2020 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis highlights confidence in growing sales with margin expansion, fueled by in-market brands and a rich pipeline, at Annual Meet the Management investor event |
| 19 Nov 2020 |
9:30 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy |
| |
2:43 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
New data at ASH to reinforce breadth of Novartis hematology portfolio across multiple blood cancers and serious hematologic diseases |
| |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis set to achieve 100% renewable electricity in its European operations |
| 13 Nov 2020 |
3:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
New Novartis analyses for investigational inclisiran demonstrate consistently effective and sustained LDL-C reduction at month 17 regardless of age and gender |
| 06 Nov 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis provides update on CAN-COVID trial in hospitalized patients with COVID-19 pneumonia and cytokine release syndrome (CRS) |
| 05 Nov 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Cosentyx® shows early synovitis reduction in patients with psoriatic arthritis in first-of-its-kind study |
| 02 Nov 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces positive results from a Phase IV study showing superior tolerability and efficacy of Aimovig® (erenumab) compared with topiramate in migraine prevention |
| 30 Oct 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia |
| 28 Oct 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces collaboration with Molecular Partners to develop two DARPin® therapies designed for potential use against COVID-19 |
| 27 Oct 2020 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis delivers solid Q3 performance with 11% core operating income growth, net sales in line with prior year, strong pipeline progression. Upgrades full year core operating income guidance. |
| 26 Oct 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis presents promising interim Phase II data of potential first-in-class oral therapy iptacopan (LNP023) in rare renal disease C3 glomerulopathy (C3G) |
| 16 Oct 2020 |
12:30 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis receives positive CHMP opinion for Leqvio®* (inclisiran), a potential first-in-class siRNA for the treatment of high cholesterol |
| 01 Oct 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Zolgensma® data including patients with more severe SMA at baseline further demonstrate therapeutic benefit, including prolonged event-free survival, increased motor function and milestone achievement |
| 23 Sep 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Provides Update on AVXS-101 Intrathecal Clinical Development Program |
| 19 Sep 2020 |
3:25 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Piqray® data show survival benefit for patients with HR+/HER2- advanced breast cancer with a PIK3CA mutation |
| |
3:20 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis reports late-breaking data from Phase III COMBI-i trial of spartalizumab (PDR001) with Tafinlar® and Mekinist® in advanced melanoma |
| 16 Sep 2020 |
10:02 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Tafinlar® + Mekinist® demonstrates long-term, relapse-free survival benefit for high-risk, stage III melanoma patients in study published in NEJM |
| |
3:24 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond |
| 14 Sep 2020 |
11:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
European Medicines Agency (EMA) approves safety label update for Novartis Beovu® |
| |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis reports positive topline results from the first Phase III trial of Beovu® versus aflibercept in patients with diabetic macular edema (DME) |
| 11 Sep 2020 |
4:05 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis data show early treatment with Mayzent® (siponimod) delays disability progression and show benefits in cognitive performance in patients with secondary progressive multiple sclerosis (SPMS) |
| |
4:00 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis presents data at ACTRIMS-ECTRIMS for Kesimpta® (ofatumumab) in newly diagnosed treatment-naïve adults with relapsing multiple sclerosis |
| 08 Sep 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis data at ACTRIMS-ECTRIMS highlight the strength of leading multiple sclerosis (MS) portfolio with life-changing therapies for people across the MS spectrum |
| 07 Sep 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings |
| 01 Sep 2020 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces ambitious ESG targets to increase access to medicines and achieve full carbon neutrality |
| 30 Aug 2020 |
7:30 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis new analysis shows high consistency in lowering LDL-C in individual response with investigational inclisiran |
| 29 Aug 2020 |
11:30 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces positive results from Phase II study of LNP023 in patients with paroxysmal nocturnal hemoglobinuria (PNH) |
| 26 Aug 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis investigational novel STAMP inhibitor asciminib (ABL001) meets primary endpoint of Phase III chronic myeloid leukemia study |
| 22 Aug 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis provides update on Phase III study evaluating investigational spartalizumab (PDR001) in combination with Tafinlar® + Mekinist® in advanced melanoma |
| 20 Aug 2020 |
6:30 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
FDA approves Novartis Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for patients with relapsing multiple sclerosis |
| 17 Aug 2020 |
6:11 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces US District Court for the District of Delaware upholds validity of Gilenya® (fingolimod) dosage regimen patent |
| 05 Aug 2020 |
10:01 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces NEJM publication of Phase III ASCLEPIOS trials demonstrating superior efficacy of ofatumumab in patients with relapsing multiple sclerosis |
| 04 Aug 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis announces Kymriah® meets primary endpoint at interim analysis of pivotal study in follicular lymphoma |
| 03 Aug 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Cosentyx® receives EU approval for first-line systemic treatment in pediatric psoriasis |
| 27 Jul 2020 |
8:29 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Sandoz announces plans for joint investment to help strengthen future of antibiotics manufacturing in Europe |
| 24 Jul 2020 |
12:36 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Adakveo® receives positive CHMP opinion for the prevention of recurrent vaso-occlusive crises in patients with sickle cell disease |
| 21 Jul 2020 |
6:00 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis delivered strong H1 performance. FY 2020 guidance confirmed at higher end for core operating income and lower end for sales. |
| 16 Jul 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis launches first-of-its-kind not-for-profit portfolio of medicines for symptomatic treatment of COVID-19 |
| 07 Jul 2020 |
6:15 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU |
| 01 Jul 2020 |
5:13 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Sandoz reviewing options after Federal Circuit upholds lower court ruling in biosimilar Erelzi® case |
| 29 Jun 2020 |
7:45 am |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options |
| 26 Jun 2020 |
12:37 pm |
GNW
|
|
|
NOVARTIS AG CHF0.50(REGD) (0QLR) |
Novartis Cosentyx® gains positive CHMP opinion for pediatric psoriasis, reinforcing established efficacy and safety profile |